Talon Private Wealth’s Moderna MRNA Stock Holding History

Talon Private Wealth’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$2.21K	Buy	+80	New	+$2.11K	﹤0.01%	286

Other funds holding MRNA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Talon Private Wealth's MRNA Position: Q2 2025 in Review

Talon Private Wealth opened a new position in Moderna (MRNA) in Q2 2025: 80 shares worth $2.21K. The stake represents ﹤0.01% of the portfolio and ranks #286 among its holdings.

674 funds tracked by Wall St. Rank hold MRNA as of Q2 2025.

Talon Private Wealth held 80 shares of Moderna worth $2.21K as of Q2 2025.
Moderna was a new Talon Private Wealth position in Q2 2025.
Moderna made up ﹤0.01% of Talon Private Wealth's portfolio in Q2 2025, its #286 holding.
674 funds tracked by Wall St. Rank held Moderna as of Q2 2025.

Based on Talon Private Wealth's 13F filing for Q2 2025, filed 14 Aug 2025.